Here we describe the design, synthesis, and evaluation of physicochemical and pharmacological properties of D 4 dopamine receptor ligands related to N-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide (2). Structural features were incorporated to increase affinity for the target receptor, to improve selectivity over D 2 and σ 1 receptors, to enable labeling with carbon-11 or fluorine-18, and to adjust lipophilicity within the range considered optimal for brain penetration and low nonspecific binding. Compounds 7 and 13 showed the overall best characteristics: nanomolar affinity for the D 4 receptor, >100-fold selectivity over D 2 and D 3 dopamine receptors, 5-HT 1A , 5-HT 2A , and 5-HT 2C serotonin receptors and σ 1 receptors, and log P=2.37-2.55. Following intraperitoneal administration in mice, both compounds rapidly entered the central nervous system. The methoxy of N-[2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3-methoxybenzamide (7) was radiolabeled with carbon-11 and subjected to PET analysis in non-human primate. [
Introduction
The dopamine D 4 receptor belongs to the D 2 -like receptor family which is characterized by its ability to interact with G i/o proteins resulting in inhibition of adenylyl cyclase. Early interest in the D 4 receptor originated from the finding that the D 2 -like receptor antagonist clozapine, an atypical antipsychotic drug with high antipsychotic efficacy and reduced extrapyramidal and neuroendocrine side effects, had 10 times higher affinity for this receptor than for other D 2 -like receptor subtypes. 1, 2 This resulted in an intense search for dopamine D 4 antagonists. 3 However, L-745,870 (Chart 1), one of the first highly D 4 -selective antagonists to be reported, failed to show antipsychotic potential in animal models. 4 In placebocontrolled clinical trials, the more bioavailable congener of 1 (L-745,870) named L-750,667 (Chart 1) did not alleviate any of the symptoms of schizophrenia. 5 Instead, there was a trend toward a worsening of psychotic symptoms. Although these findings seemed to exclude the D 4 receptor as an antipsychotic drug target, later in vitro studies with 1 provided evidence for its weak partial agonist activity. 6, 7 Subsequently, the selective D 4 ligand FAUC 213 (Chart 1), structurally related to 1, was characterized as a "neutral antagonist" using a different measure of functional activity (thymidine incorporation instead of cAMP accumulation). 8 Years later, a dose of this same ligand, which reduced amphetamine-induced increased locomotor activity, was demonstrated to have atypical antipsychotic potential in animal models predictive of antipsychotic efficacy in humans. 9 This is in contrast to the structurally distinct D 4 -selective neutral antagonist PNU-101,387G (sonepiprazole) (Chart 1), which has no demonstrable antipsychotic activity in humans. 10 The D 4 receptor has been suggested as a candidate gene for novelty seeking behavior [11] [12] [13] [14] and attention deficit hyperactivity disorder (ADHD a ), [15] [16] [17] [18] although the latter association or its basis has been questioned. [19] [20] [21] While certain antagonists of the D 4 receptor reduced hyperactivity in a neonatal 6-hydroxydopamine lesioned rat model of ADHD, 22 the hyperactivity due to neonatal lesioning appears to be mediated by compensatory changes in serotonin transporters. 23 More recently, the D 4 agonist A-412997 (Chart 1) was shown to improve cognitive function in both a five-trial inhibitory avoidance paradigm and the social recognition model, which are two animal models thought to be predictive of anti-ADHD efficacy. 24 The D 4 receptor has been implicated in the control of penile tumescence. For instance, D 4 selective agonists like ABT-724 *To whom correspondence should be addressed. Phone: þ39 080 5442798. Fax: þ39 080 5442231. E-mail: leopoldo@farmchim.uniba.it.
a Abbreviations: ADHD, attention deficit hyperactivity disorder; PET, positron emission tomography; GPCR, G-protein-coupled receptor; BBB, blood-brain barrier.
(Chart 1) produce erectogenesis in animal models without nausea. 25 However, studies in rats support a role for the D 3 receptor, but not the D 4 receptor, in the induction of penile erection by D 2 -like agonists in rodents. 26 Although the D 4 receptor is expressed at low levels in the brain, much higher densities of this receptor are expressed in the retina. 27 Dopamine, via D 4 receptors, normally modulates the cascade that couples light responses to adenylyl cyclase activity in photoreceptor cells in the retina. 28, 29 To better understand dopamine D 4 receptor biology in vivo, a suitable D 4 receptor positron emission tomography (PET) tracer would be a powerful tool allowing noninvasive D 4 receptor imaging. A number of attempts have been made to identify a D 4 -selective PET radioligand. [30] [31] [32] [33] [34] [35] [36] In 2000, Langer and co-workers reported an attempt to visualize the dopamine D 4 receptor in primate brain with [ 11 C]PB-12 (compound 2, Table 1 ). 32 The radioligand was of little use in visualizing D 4 receptors because it exhibited a very high background due to nonspecific binding. Similar results were obtained 2 years later by Zhang and co-workers who prepared and tested [ ]YM-50001 (Chart 1) with both radioligands being unsuitable for D 4 receptor imaging with PET. 34 In each case, it was suggested that the high nonspecific binding of [ 11 C]2 could be due to its relatively high lipophilicity (ClogP = 3.72). 37 More recently, Prante and co-workers reported on the rational design of a series of pyrazolo [1,5- An adequate PET tracer for neuroreceptor visualization must fulfill many criteria: 38, 39 high affinity for the target receptor (usually in the nanomolar range); selectivity for its target (>100-fold); ease of labeling with 11 C or 18 F at high specific radioactivity; safe administration at low tracer dose; high blood-brain barrier (BBB) penetrance; inability to serve as a substrate for efflux transporters; low nonspecific binding; suitable brain pharmacokinetics in relation to radiolabel halflife (observable brain uptake and washout kinetics); lack of troublesome radiometabolites. Of particular importance with respect to BBB penetration and low nonspecific binding is tracer lipophilicity. In general, brain penetration by passive diffusion of molecules across the BBB becomes poor when the log P is greater than 4.0, molecular weight is larger than 450 Da, and the number of hydrogen bond donors is greater than 5. However, if molecules are too hydrophilic, their BBB passage is prevented as well. It has been reported for many drug classes that the optimum log P value for central nervous system (CNS) targeted drugs lies between 2.0 and 3.5. Moreover, high lipophilicity attributed to adhesion to proteins and lipids tends to increase nonspecific binding, an essentially nonsaturable component of the total tissue uptake of a radioligand. Therefore, it appears that there is an optimal range of lipophilicity for brain radioligands, wherein brain uptake is high and nonspecific binding comparatively weak. From data in the literature, log P=3.5 appears to be the acceptable upper limit of lipophilicity for a PET radioligand. 40 Here we describe the synthesis and in vitro characterization of an improved series of D 4 receptor agents derived from our lead compound 2, 41-43 which we rationally designed specifically for use as a PET radiotracer. By use of our newly developed selection criteria and assay cascade, one of a dozen compounds was selected for radiolabeling with carbon-11 and PET studies in monkey brain.
Chemistry
The synthesis of the final compounds is depicted in Scheme 1. The preparation of the target compounds required the key amines 18a-f. Among these, 4-(4-chlorophenyl)-1-piperazineethanamine (18a) and 4-(4-methylphenyl)-1-piperazineethanamine (18b) were prepared according to the literature. 44 Amines 18c-e were prepared as follows: the appropriate 1-arylpiperazine was alkylated with 2-haloethanol to the corresponding alcohol 15c-e. These latter were subsequently condensed, under Mitsunobu conditions, with phthalimide to give 16c-e, which were hydrolyzed with hydrazine hydrate to afford primary amines 18c-e. An alternative synthetic route was followed to prepare amine 18f: 1-(5-chloro-2-pyridinyl)-piperazine 45 was first alkylated with chloroacetonitrile and then treated with borane dimethyl sulfide complex to afford the desired amine 18f. The final compounds were prepared by condensing 3-methoxy-or 4-fluorobenzoic acid with amines 18a-f in the presence of 1,1 0 -carbonyldiimidazole.
Results and Discussion
Lipophilicity Evaluation. The pivotal role of PET tracer lipophilicity is well recognized, and it has been reviewed in depth by Waterhouse. 40 Lipophilicity can be evaluated in various theoretical and experimental ways. The most common experimental lipophilicity measurement involves partitioning of a compound between octanol and aqueous solution (log P). The log P refers to partitioning of the neutral molecule species and log D 7.4 the partitioning of all species present in solution at a given pH, which accounts for solubility effects associated with ionization. When lipophilicity is expressed as log P or log D 7.4 , compounds that seem most effective for Chart 1. Representative Selective Dopamine D 4 Receptor Ligands imaging have log P or log D 7.4 of <3.5. On such a basis, we have modified our reference compound 2 and designed compounds 4-14 which showed computer estimated values of lipophilicity below the guideline value (3.5). Then, the experimental log P, log D 7.4 , and pK a values of 4-14 were determined by potentiometric titrations (Table 1) . Considering the pK a values of target compounds, it can be deduced that the percentage of protonated species at physiological pH is not very high, and this accounts for the similarities between log P and log D 7.4 values. Experimental log P values were, however, different from the calculated values. The largest difference (1.05 log units) was shown in the case of compound 7 (ClogP=1.50 vs log P=2.55), whereas the smallest (0.26 log units) was for 12 (ClogP = 2.81 vs log P = 2.37). While the explanation of such differences is beyond the scope of this study, these data confirm that the lipophilicity of a molecule is the result of all intermolecular solute-solvent interactions in both aqueous and organic solvents and not only the sum of the contribution of isolated fragments. In fact, the difference between log P values and ClogP can, and in our case does, vary among structurally related compounds. For example, compounds 5 and 11 have a difference between the calculated and experimental log P of 0.37 and 0.93, respectively; for 7 and 13, the difference was 1.05 and 0.43, respectively. In spite of these discrepancies, all the experimental log P values were below the guideline value with the exception of those for 9 and 11, which had log P values of 3.75 and 3.79, respectively. Therefore, in those cases when lipophilicity must fall within a narrow range and ClogP values are borderline, an experimental determination is prudent.
Rational Design and Structure-Affinity Relationships. All the target compounds were designed taking into account the structural requirements for an adequate PET tracer as detailed in the Introduction. Compounds 4-8 have a methoxy group Table 1 ). The modification was limited to the aryl group linked to the piperazine ring. In particular, replacement of -Cl in 2 with -CH 3 led to 4 which has only 2-fold lower affinity for the D 4 receptor than 2. On the other hand, replacement of -Cl in 2 with -CN gave 6 which had considerably less affinity than 2 (K i =63.95 nM). Replacement of the phenyl ring in 2 with a 2-pyridyl gave 8 which demonstrated only 2-fold less affinity than 2. In a previous study we found that N-[4-[4-(1,2-benzisoxazol-3-yl)piperazin-1-yl]butyl]-3-methoxybenzamide displayed high affinity (K i = 7.58 nM) for the D 4 receptor. 46 Thus, we wanted to evaluate if a shorter alkyl chain (ethyl vs butyl) increased affinity for the D 4 receptor. Compound 5 displayed higher affinity (K i =1.93 nM) than either the butyl homologue cited above and 2. The replacement of 4-chlorophenyl group in 2 by the 3-cyano-2-pyridinyl one (7) was undertaken because a number of D 4 ligands reported in the literature were characterized by such a group. 47 This replacement was particularly beneficial because 7 had improved affinity for the D 4 receptor (K i = 1.52 nM). A second set of derivatives were designed by replacing the 3-methoxybenzamide of 2, 4-8 with a 4-fluorobenzamide (compounds 9-14, Table 1 ). The 4-fluorobenzamides 9-14 possessed higher D 4 affinities than their 3-methoxy counterparts. The most notable increase in affinity was observed in the case of 1,2-benzisoxazol-3-yl derivative 11 which has approximately 6-fold higher affinity than the 3-methoxy analogue 5. Also, the rank order of binding affinity among the derivatives was practically unchanged with the sole exception of 3-cyano-2-pyridinyl 13, which had slightly less affinity than the 1,2-benzisoxazol-3-yl 11. All in all, the proposed structural modifications led to a range of D 4 ligands possessing affinities higher than the lead compound 2. Among them, 11 and 13 demonstrated subnanomolar K i values. Subsequently, all compounds were evaluated at 1 μM for their ability to displace [ (Table 2) . Strong displacement was observed for compounds 5 and 11, indicating that they have significant affinity for the D 2L receptor. Moderate displacement (40-50%) was observed for 9, 10, 13, and 14, whereas 2, 4, 6-8, and 12, had practically no effect on the specific binding of the radioligand to the D 2L receptor. Because some compounds touted as being D 4 -selective actually have high affinity for the σ 1 receptor, 48 all compounds were evaluated at 1 μM for their ability to displace specifically bound [ (Table 2) . Little or no displacement (<40%) was observed for all the tested compounds, indicating that they have little or no affinity for the σ 1 receptor. Taken together, these data indicate that compounds 7 and 13 have high selectivity for the D 4 receptor over D 2L and σ 1 receptors. Therefore, both compounds were evaluated further for potential interactions with selected other G-protein-coupled receptors (GPCRs) and for their functional properties at the D 4 receptor. While 7 and 13 had a similar binding profile for D 3 , CB 1 , and 5-HT 2C receptors, 7 had significantly less radioligand displacing activity at 5-HT 1A and 5-HT 2A receptors than 13 (Table 3 ). Both 7 and 13 were able to stimulate D 4 receptors measured as a decrease in forskolin-stimulated levels of cAMP accumulation (Figure 1 ), indicating that they have agonist properties.
Considering that a PET tracer needs to have high affinity for the target receptor and, in particular, it is preferable that the B max clearly exceeds the K d of the ligand (ideally B max /K d >10), 49 one could ask if compounds 7 and 13 meet this requirement. D 4 ) only in the hippocampus. 52 In contrast, Primus and co-workers used [ 3 H]NGD-94-1 and reported B max values ranging from 8.9 to 28.9 fmol 3 (mg of protein) -1 in hippocampal, cortical, and limbic regions. 50 Importantly, these values originate from homogenized tissue and do not necessarily reflect the tissue heterogeneity to be encountered in the intact brain in vivo. 53 Therefore, the concentration of D 4 receptor sites determined by indirect methods should be viewed with some caution, making the lack of precise B max values for the D 4 receptor in the brain difficult to estimate the affinity value to be targeted when developing a D 4 PET tracer. Since compounds 7 and 13 had the best combination of lipophilicity, high affinity (K i in the low nanomolar range), and selectivity for the D 4 receptor of the ligands listed in Table 1 , they were selected for further testing in order to assess their potential of use in vivo as PET tracers.
Disposition Studies in Mice with Compounds 7 and 13. Mice were given an intraperitoneal dose of the 4-fluorobenzamide 13 and the 3-methoxybenzamide 7 and were sacrificed at various times thereafter to obtain basic information on the concentrations of unchanged compound achieved in brain and their relationship with plasma concentrations. The presence of 1-(6-cyano-2-pyridyl)piperazine was also monitored in parallel because many N-substituted 1-arylpiperazines are reported to undergo metabolic N-dealkylation. 54 As shown in Table 4 , compound 13 rapidly reached the systemic circulation with maximal plasma concentrations (C max ) 15 min after dosing (i.e., the first sampling time). However, these plasma concentrations were low and variable (0.13 ( 0.10 μg/mL) and rapidly fell below the limit of quantitation after 30 min (i.e., less than 0.1 μg/mL, using 0.2 mL of mouse plasma). Compound 7 peaked slightly later, yielding a higher mean C max (0.37 ( 0.21 μg/mL at 30 min), and these concentrations were consistently detected only up to 60 min after dosing. Thus, in both cases the data did not permit adequate determination of a terminal elimination phase and the calculation of conventional pharmacokinetic parameters. This behavior may be partly due to a large presystemic biotransformation after intraperitoneal dosing because 1-arylpiperazine derivatives are generally extensively biotransformed before reaching the systemic circulation, and their clearance is almost entirely due to hepatic metabolism. 54 Concentrations of 1-(6-cyano-2-pyridyl)piperazine, however, were low for 7 (0.10-0.2 μg/mL) or not detectable for 13 (<0.1 μg/mL) within 30-60 min of intraperitoneal dosing (10 mg/kg). This suggests that N-dealkylation of the aliphatic side chain may have contributed to but did not account for the first-pass effect and clearance of 7 and 13 in mice. Brain uptake was rapid for both derivatives: quantifiable levels were consistently evident up to 30 min for 7 and 60 min in the case of 13. Mean brain C max averaged 0.47 ( 0.20 μg/g for the 4-fluorobenzamide 13 (at 15 min post dose) and 0.14 ( 0.02 μg/g for the 3-methoxybenzamide 7 (at 30 min post dose), giving rise, at these times, to a mean brain-to-plasma concentration ratio higher for the more lipophilic fluorobenzamide derivative. While an accurate determination of whole brain exposure and brain-to-plasma distribution ratios was not possible, rough estimates based on the limits of quantification further suggested that the fluorobenzamide is concentrated in brain tissue of mice more than its methoxybenzamide analogue. In both cases the brain concentrations of the dealkylated metabolite 1-(6-cyano-2-pyridyl)piperazine were below the limit of detection within 180 min of dosing (about 0.1 μg/g, using approximately 200 mg of brain tissue).
These data indicated that both 7 and 13 can reach the brain and have fast uptake kinetics ideal for a PET tracer. Because of the relative ease of radiolabeling, compound 7 was selected as a PET D 4 tracer candidate.
Radiosynthesis of [ PET Studies in Rhesus Monkey. After intravenous injection of [ 11 C]7 in a male rhesus monkey, the uptake of [
11 C]7 in all brain regions peaked at 45 s and then the radioactivity rapidly declined, suggestive of no specific binding in these regions (Figure 2 ). About 3.1% of the injected radioactivity reached the brain at peak time. In contrast, radioactivity was markedly higher in the retina compared to the brain regions examined (Figure 3 ). The ratio of retinal radioactivity to the cerebral radioactivity was more than 6-fold at the end of the scanning period.
While . 27 The presence of the radioligand in the region of the retina suggests that the compound was able to cross the blood-retina barrier, and therefore, it also has the potential to cross the BBB because it has been reported that both barriers display very similar properties. 55 Moreover, the lack of a persistent signal in other CNS structures indicates that [ 
Conclusions
We report here on a systematic strategy for discovering ligands suitable as PET radiotracers for imaging of dopamine D 4 the receptor in the CNS. Starting from our high-affinity ligand 2 and guided in part by previous structure-activity relationship studies from our laboratories and other laboratories, we developed an assay cascade leading to the design of a set of compounds possessing chemical features amenable to carbon-11 or fluorine-18 labeling and calculated log P values within the range that is considered optimal for a radiotracer. (13) . Compounds 7 and 13 showed K i values of 1.52 and 0.93 nM, respectively, and >100-fold selectivity over the off-target receptors. When tested in disposition studies in mice to evaluate their BBB penetrance and first-pass metabolism characteristics, both 7 and 13 rapidly entered the brain and, importantly in this context, were also rapidly cleared from the brain. Carbon-11 radiolabeling of the phenol precursor 19 resulted in the 3-methoxybenzamide 4 receptors. While more questions may need to be answered and further improvements could be made, we believe that 7 represents a significant step forward in the development of a CNS PET tracer selective for the dopamine D 4 receptor, having allowed for the first time CNS imaging of D 4 receptor in a structure with the highest known density of this receptor subtype. Importantly, the strategy we worked out appears to serve as a suitable paradigm for developing additional D 4 -selective PET tracers which would have higher affinity presumably making them suitable for imaging in brain regions having a very low density of the D 4 receptor. Finally, because of its high affinity and specificity, compound 7 in the tritiated form may have utility as a radioligand for studying the distribution and density of the dopamine D 4 receptor protein in ex vivo or in vitro studies.
Experimental Section
Chemistry. The purity of the tested compounds 2, 4-14 has been assessed by RP-HPLC and combustion analysis. All compounds showed g95% purity. Column chromatography was performed with 1:30 Merck silica gel 60A (63-200 μm) as the stationary phase. Melting points were determined in open capillaries on a Gallenkamp electrothermal apparatus. Elemental analyses (C, H, N) were performed on Eurovector Euro EA 3000 analyzer; the analytical results were within (0.4% of the theoretical values for the formula given.
1 H NMR spectra were recorded at 300 MHz on a Varian Mercury-VX spectrometer. All spectra were recorded on free bases. All chemical shift values are reported in ppm (δ). Recording of mass spectra was done on an HP6890-5973 MSD gas chromatograph/mass spectrometer; only significant m/z peaks, with their percentage of relative intensity in parentheses, are reported. ESI þ -MS/MS analysis were performed with an Agilent 1100 series LC-MSD trap system VL workstation. All spectra were in accordance with the assigned structures. RP-HPLC analysis was performed on a Perkin-Elmer series 200 LC instrument using a Phenomenex Gemini RP-18 column, (250 mm Â 4.6 mm, 5 μm particle size) and equipped with a Perkin-Elmer 785A UV/vis detector setting of λ = 254 nm. Compounds 2 and 4-14 were eluted with CH 3 OH/H 2 O/Et 3 N, 4:1:0.01, v/v at a flow rate of 1 mL/min. When necessary, a standard procedure was used to transform final compounds into their hydrochloride salts. The following compounds were synthesized according to published procedures: 1-(4-chloro-2-pyridinyl)-piperazine, 45 1-(3-cyano-2-pyridinyl)piperazine, 56 4-(4-chlorophenyl)-1-piperazinoethanamine (18a), 44 4-(4-methylphenyl)-1-piperazinoethanamine (18b). 44 The NMR and MS spectra of compounds 2, 4, and 8 have been reported earlier.
42,46

3-[4-(2-Hydroxyethyl)-1-piperazinyl]-1,2-benzisoxazole (15c).
A solution of 3-(1-piperazinyl)-1,2-benzisoxazole (0.6 g, 2.96 mmol) in dioxane (15 mL) was treated with anhydrous K 2 CO 3 (1.43 g, 10.3 mmol) and KI (0.04 g, 0.2 mmol). After addition of 2-bromoethanol (1.2 mL, 17.3 mmol) the mixture was refluxed overnight. The solvent was distilled off, and the residue was partitioned between H 2 O (20 mL) and CHCl 3 (20 mL). The organic phase was separated, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure. The crude residue was chromatographed (CHCl 3 /MeOH 19:1, as eluent) to afford the pure alcohol as a white solid (0.56 g, 77% yield). (46), 100 (40).
4-[4-(2-Hydroxyethyl)-1-piperazinyl]benzonitrile (15d
General Procedure for Preparation of Compounds 16c-e. Diethyl azodicarboxylate (2.25 mmol) was added to a stirred solution containing the appropriate alcohol 15c-e (1.5 mmol), triphenylphosphine (1.5 mmol), and phthalimide (2.25 mmol) in anhydrous THF (20 mL). The resulting mixture was stirred at room temperature under anhydrous condition until the alcohol disappeared (TLC). Then the mixture was partitioned between AcOEt (20 mL) and H 2 O (20 mL). The organic layer was separated, dried (Na 2 SO 4 ), and concentrated in vacuo. The crude residue was chromatographed as detailed below to afford pure compounds as pale yellow solids in quantitative yield. (17) . A stirred mixture of 1-(5-chloropyridin-2-yl)piperazine (2.25 g, 11.4 mmol), chloroacetonitrile (0.60 mL, 9.5 mmol), and an excess of K 2 CO 3 in acetonitrile (50 mL) was refluxed overnight. After cooling, the mixture was evaporated to dryness. Then H 2 O was added to the residue. The aqueous phase was extracted with CH 2 Cl 2 (2Â30 mL), and the collected organic layers were dried over Na 2 SO 4 and evaporated under reduced pressure. The crude residue was chromatographed (CHCl 3 /AcOEt, 9:1, as eluent) to give pure 17 as a pale yellow semisolid (2.0 g, 90% yield). 1 (21) . General Procedure for Preparation of Amines 18c-e. Phthalimide derivative 16c-e (1.5 mmol) was mixed with an excess of hydrazine hydrate in EtOH (20 mL) and refluxed for 8 h. Then the mixture was cooled on ice bath and acidified with concentrated HCl. The mixture was refluxed for 1 h. Then the mixture was cooled and filtered. The filtrate was concentrated under reduced pressure, and the residue was partitioned between 10% aqueous NaOH and CHCl 3 . The separated organic layer was dried over Na 2 SO 4 and concentrated in vacuo to give the pure amine in 70-80% yield.
4-(1,2-Benzisoxazol-3-yl)-1-piperazinoethanamine (18c). 4-(5-Chloropyridin-2-yl)piperazineethanamine (18f). Boranemethyl sulfide complex as 10.0 M BH 3 in excess methyl sulfide (1.6 mL, 16 mmol) was dropped into an ice cooled solution of nitrile 17 (5.1 mmol) in anhydrous THF (10 mL), under stirring. After being refluxed for 4 h, the reaction mixture was cooled at -10°C and MeOH was added dropwise very carefully until gas evolution ceased. The mixture was treated with 3 N HCl (20 mL) and was refluxed for 1 h. After cooling, the mixture was alkalized with 3 N NaOH and extracted with CH 2 Cl 2 (2 Â 30 mL). The collected organic layers were dried over Na 2 SO 4 and the solvent was evaporated under reduced pressure to give the pure amine as a white semisolid (64% yield). General Procedure for Preparation of Compounds 5-7, 9-14, 19. A mixture of the appropriate benzoic acid (0.48 mmol) and 1,1 0 -carbonyldiimidazole (0.50 mmol) in 10 mL of anhydrous THF was stirred for 8 h. A solution of amine 18a-f (0.48 mmol) in anhydrous THF (10 mL) was added, and then the mixture was stirred until the benzoic acid disappeared (TLC). The reaction mixture was partitioned between AcOEt (20 mL) and H 2 O (20 mL). The separated organic layer was washed with a saturated aqueous solution of Na 2 CO 3 (20 mL), dried (Na 2 SO 4 ), and concentrated in vacuo. The crude residue was chromatographed as detailed below to afford the pure arylcarboxamide in 40-50% yield. Lipophilicity Data. Lipophilicity data of compounds 2 and 4-13 were obtained by the pH metric technique using a GlpK a apparatus (Sirius Analytical Instruments Ltd., Forrest Row, East Sussex, United Kingdom) as described elsewhere. 57 The low aqueous solubility of the investigated compounds required pK a measurements to be performed in the presence of methanol as cosolvent. Three separate 20 mL semiaqueous solutions of approximately 5 Â 10 -5 M, in 20-50% w/w of MeOH, were initially acidified with 0.5 M HCl to pH 3.5. The solutions were then titrated with 0.5 M KOH to pH 11. The initial estimates of the p s K a values, which are the apparent ionization constants in the mixed solvent, were obtained by Bjerrum plots. These values were then refined by a weighted nonlinear least-squares procedure (Refinement Pro 1.0 software) to create a multiset, where the refined values were extrapolated to zero cosolvent concentration using the Yasuda-Shedlovsky equation. 58 To obtained log P data, at least three separate titrations were performed on each compound, of approximately 5 Â 10 -5 M, using various n-octanol/water ratios (from 0.005 to 1). The biphasic solutions were initially acidified to pH 3.5 with 0.5 M HCl and then titrated with 0.5 M KOH to pH 11. The obtained data were refined as described above. The log P values were obtained by the multiset approach, as described elsewhere. 57 All titrations were carried out at 25 ( 0.1°C under an inert nitrogen gas atmosphere to exclude CO 2 .
N-[2-[4-(3-
Radiosynthesis of [ 11 C]7. Carbon-11 was produced by 14 N(p, R) 11 C nuclear reaction using CYPRIS HM-18 cyclotron (Sumitomo Heavy Industry Co. Ltd., Tokyo, Japan). [ 11 C]CH 3 I with high specific activity was produced by the single-pass I 2 method as described previously. 59 By the nuclear reaction and a successive hot atom process, [ 11 C]CH 4 (total radioactivity: 44 GBq) was produced in the target chamber at an initial pressure of 15 bar with 18 MeV protons (14.2 Mev on target). [ 11 C]CH 4 was passed through a heated I 2 column once and converted to [ 11 C]CH 3 I, which was collected in a reaction vessel containing a 300 μL of anhydrous DMF solution of desmethyl precursor 19 (1 mg) and NaOH (10 μL, 0.5 N) at -15 to -20°C. After radioactivity reached a plateau, the reaction mixture was heated at 70°C for 3 min. The HPLC solvent was added to the reaction vessel to terminate the reaction. The radioactive mixture was applied to an HPLC purification system (SHISEIDO CAPCELL PAK C18 UG80 column, 10 mm Â 250 mm; mobile phase CH 3 OH/ H 2 O/triethylamine, 6/4/0.1%; flow rate, 5 mL/min; λ = 254 nm). The fraction corresponding to [ 11 C]7 was collected in a flask containing 100 μL of ascorbic acid (25%) and evaporated to dryness under a vacuum. The residue was dissolved in 3 mL of saline (pH 7.4) for animal experiments. At the end of synthesis, 210-440 MBq (n = 4) of [ 11 C]7 was obtained as an intravenous injectable solution. The radiochemical purity and specific activity of [ 11 C]7 were assayed by analytical HPLC (SHISEIDO CAPCELL PAK C18 UG80 column, 10 mm Â 250 mm; mobile phase CH 3 OH/H 2 O/triethylamine, 6/4/0.1%; flow rate, 5 mL/min; λ = 254 nm). The identity of [ 11 C]7 was confirmed by coinjection with an authentic nonradioactive sample. The amount of carrier in the final product solution was measured by the same analytical HPLC. The radiochemical purity and specific activity was>99% and 2770-3890 GBq/μmol (n = 4), respectively.
Biological Methods. 
60-62
The expression levels of the different receptor subtypes in individual clonal lines were determined by radioligand saturation isotherm binding utilizing standard rapid filtration techniques and cell membrane preparations as described by us previously. 63 Cloned human σ 1 receptors were stably expressed in human MCF-7 cells as described by us previously, because MCF-7 cells lack specific binding for [ binding buffer at the pH at that temperature. Radioactivity bound to filters was quantified in a scintillation counter. Membrane protein concentrations were determined using the bicinchonic acid protein reagent (BCA) and a bovine serum albumin standard curve. Membranes protein concentrations varied from 0.01 to 0.05 mg/mL. Binding affinities (K i ) were determined by competition binding with fixed concentrations of the radioligands described in Table 5 . With the exception of 6, 7, and 12, which were dissolved in DMF, all compounds were solubilized in DMSO at concentrations ranging from 1 to 10 mM. These nonaqueous solution stocks were then diluted at least 1:1000 v/v in the final assay solution.
3. Calculations and Data Analysis. All points were run in triplicate. Each experiment was repeated three to four times, and averaged values were reported with their standard deviation or standard error. The inhibition constant (K i ) values were calculated from IC 50 values using the Cheng-Prusoff equation:
. 64 In cases where the displacement was>20% but less than 100% at the highest concentration of inhibitor, the bottom of the curve fit was set to zero so that accurate IC 50 values could be calculated. A 95% confidence interval was employed for all curve-fitting procedures using Graphpad's Prism software, version 4.0. Council, 1996) . Concentrations of the selected compounds were determined by HPLC with UV detection (λ = 264 nm). Briefly, to 0.2 mL of plasma, 0.01 mL of 1 M NaOH, 0.03 mL of the internal standard 1-(2-thiazolyl)piperazine (10 μg/mL), and 5 mL of dicloromethane were added. After being shaken, samples were centrifuged, and to the organic extract 0.15 mL of mobile phase was added. After further shaking and centrifugation, 0.1 mL of the mobile phase was injected onto the HPLC system. Brains were homogenized in distilled water (1 g/10 mL), and an amount of 2 mL of the homogenate was processed as above. Chromatography was performed on a reversed-phase column XTerra RP 18 (4.6 mm Â 150 mm, 5 μm particle size). The mobile phase was CH 3 CN/ 0.005 M KH 2 PO 4 (pH 3.5) (5:95, v/v) (solvent A) and CH 3 CN/ 0.005 M KH 2 PO 4 (pH 3.5) (70:30, v/v) (solvent B). The HPLC system was set up to operate at a flow rate of 1 mL/min, following a simple gradient: step 1, from the initial condition (100% solvent A) to 20% solvent A (80% B) in 12 min; step 2, from 20% to 100% solvent A (from 80% to 0% of solvent B) in 2 min. The total run time was 18 min.
The retention times were 8.7 min for 7, 8.8 for 13, 4.5 min for 1-(6-cyano-2-pyridyl)piperazine, and 7.7 min for internal standard. The limit of quantification was about 100 ng/mL or ng/g, using 0.2 mL of plasma or about 200 mg of tissue. At these concentrations, the coefficients of variation (CV) were generally between 10% and 15%, and all higher concentrations gave CV between 5% and 10% for all compounds in both tissues.
5. Monkey PET Scan. PET scans were performed on a male rhesus monkey (Macaca mulatta) weighing 4.4 kg. The animal was maintained and handled in accordance with recommendations by the U.S. National Institutes of Health and our institutional guidelines (National Institute of Radiological Sciences). The studies were approved by the Animal Ethics Committee of the National Institute of Radiological Sciences, Chiba, Japan. PET scan was performed using a high-resolution SHR-7700 PET camera (Hamamatsu Photonics K.K., Japan) designed for laboratory animals, which provides 31 transaxial slices 3.6 mm (center-to-center) apart, a 33.1 cm field of view, and spatial resolution of 2.6 mm full width at half-maximum. 65 The monkey was anesthetized with ketamine at 10 mg/kg im (Ketalar, Sankyo Co. Ltd., Japan) with a head fixation device to ensure accuracy of repositioning. 66 Following transmission scans for attenuation correction using a 68 Ge-68 Ga source for 20 min, a dynamic emission scan in 3D acquisition mode was immediately performed after intravenous injection of [ 11 C]7 (38.5 ( MBq; specific radioactivity, 2.9 TBq/μmol at injection) for 90 min (0.5 minÂ6 frames, 1 minÂ7 frames, 2 minÂ20 frames, 5 minÂ 8 frames). Dynamic emission scan images were reconstructed with filtered back-projection using a 4.0 mm Colsher filter. Volumes of interest (VOIs) were placed on the hippocampus, entorhinal cortex, and striatum using PMOD image analysis software (PMOD Group, Zurich, Switzerland) with reference to the magnetic resonance (MR) image of the monkey brain. The MR image was acquired with a 1.5 T gyroscan S15/ACS2 (Philips Electronic, Eindhoven, The Netherlands) by means of a three-dimensional T 1 -weighted spin-echo sequence. The tracer uptake in each VOI was estimated as percent of injected dose per unit volume (% ID/mL).
